BACKGROUND: The approval of sunitinib, sorafenib and temsirolimus has dramatically altered the management of renal cell carcinoma (RCC). Bevacizumab plus IFN may also be added to the therapeutic armamentarium. Axitinib (AG-013736) is an oral and selective tyrosine kinase inhibitor. OBJECTIVE: Data supporting the development of axitinib for RCC are reviewed. METHODS: Preclinical and clinical data available for axitinib for RCC are presented. RESULTS: Axitinib inhibits VEGFR-1, VEGFR-2 and VEGFR-3 with picomolar potencies, and PDGFR-alpha, PDGFR-beta and c-kit with nanomolar potencies. Phase II clinical trials of axitinib in pretreated RCC following sorafenib or cytokine treatment have demonstrated promising activity accompanied by a favorable toxicity profile. Further development of axitinib for RCC is warranted.
BACKGROUND: The approval of sunitinib, sorafenib and temsirolimus has dramatically altered the management of renal cell carcinoma (RCC). Bevacizumab plus IFN may also be added to the therapeutic armamentarium. Axitinib (AG-013736) is an oral and selective tyrosine kinase inhibitor. OBJECTIVE: Data supporting the development of axitinib for RCC are reviewed. METHODS: Preclinical and clinical data available for axitinib for RCC are presented. RESULTS:Axitinib inhibits VEGFR-1, VEGFR-2 and VEGFR-3 with picomolar potencies, and PDGFR-alpha, PDGFR-beta and c-kit with nanomolar potencies. Phase II clinical trials of axitinib in pretreated RCC following sorafenib or cytokine treatment have demonstrated promising activity accompanied by a favorable toxicity profile. Further development of axitinib for RCC is warranted.
Authors: C Porta; G Tortora; C Linassier; K Papazisis; A Awada; D Berthold; J P Maroto; T Powles; M De Santis Journal: Med Oncol Date: 2011-07-07 Impact factor: 3.064
Authors: Matthew Scarpelli; Justine Yang Bruce; Lakeesha Carmichael; Jens Eickhoff; Jill Kolesar; Scott Perlman; Robert Jeraj; Glenn Liu Journal: Cancer Chemother Pharmacol Date: 2016-11-05 Impact factor: 3.333
Authors: Justine Yang Bruce; Peter Colin Scully; Lakeesha L Carmichael; Jens C Eickhoff; Scott B Perlman; Jill Marie Kolesar; Jennifer L Heideman; Robert Jeraj; Glenn Liu Journal: Cancer Chemother Pharmacol Date: 2015-05-29 Impact factor: 3.333
Authors: Ying Chen; Michael A Tortorici; May Garrett; Brian Hee; Karen J Klamerus; Yazdi K Pithavala Journal: Clin Pharmacokinet Date: 2013-09 Impact factor: 6.447